Printer Friendly

PERSEPTIVE BIOSYSTEMS ANNOUNCES ELECTION OF DR. WILLIAM POUNDS TO ITS BOARD OF DIRECTORS

 CAMBRIDGE, Mass., June 8 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today that Dr. William F. Pounds has been elected to the company's board of directors. Currently a professor of management at the Alfred P. Sloan School of Management at the Massachusetts Institute of Technology, Dr. Pounds also served as dean of the Sloan School from 1966 to 1980.
 Dr. Pounds was president and CEO of Rockefeller Financial Services, Inc., as well as a senior advisor to the Rockefeller family, from 1981 to 1991, and is currently a director of the Sun Company, Inc., IDEXX Laboratories, Inc., Fisher Price, Inc., The Putnam Funds, and M/A-Com, Inc.
 Noubar B. Afeyan, Ph.D., PerSeptive's chairman and CEO, commented, "Bill Pounds' wide array of experience in organizational dynamics and management, as head of one of the country's leading financial services firms, and as dean of one of the country's leading business schools, will make him a valued contributor to PerSeptive Biosystems. We are pleased to welcome him as a member of our board of directors."
 Dr. Pounds has received his B.S. degree in chemical engineering, a Masters degree in Mathematical Economics, and a Ph.D. degree all from Carnegie Mellon University. His research and teaching have focused on quantitative methods for managerial analysis, problems associated with operations management, and the theory of decision making.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R) for high resolution separations of biomolecules 10 to 1,000 times faster than conventional chromatography, ImmunoDetection(tm) for real-time immunoassays in a flow-through cartridge format and Rational Surface Design(tm) synthetic surfaces that bind biomoleclues with the high specificity of antibodies.
 -0- 6/8/93
 /CONTACT: Noubar B. Afeyan, chairman and CEO, finance, PerSeptive Biosystems, Inc., 617-621-1787/
 (PBIO)


CO: PerSeptive Biosystems, Inc. ST: Massachusetts IN: MTC SU: PER

DJ -- NE009 -- 6423 06/08/93 09:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:360
Previous Article:THERMO PROCESS SYSTEMS ANNOUNCES QUARTERLY AND YEAR-END RESULTS
Next Article:MARINER HEALTH GROUP, INC. ANNOUNCES PUBLIC OFFERING OF 3,500,000 SHARES OF COMMON STOCK
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS, INC., ANNOUNCES SETTLEMENT OF DISPUTE WITH FORMER PRESIDENT
ROBERT A. FEIN PROMOTED TO SENIOR VICE PRESIDENT, FINANCE FOR PERSEPTIVE BIOSYSTEMS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES SECOND QUARTER RESULTS
PAUL J. SEKHRI JOINS PERSEPTIVE BIOSYSTEMS AS MARKETING DIRECTOR, ANALYTICAL PRODUCTS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THE INTRODUCTION OF TWO NEW PERFUSION CHROMATOGRAPHY INSTRUMENTS
JOHN H. WEBB ELECTED CHAIRMAN OF ENERGY BIOSYSTEMS CORPORATION
REGNIER, PH.D NAMED CHIEF TECHNICAL OFFICER OF PERSEPTIVE BIOSYSTEMS; CO-INVENTOR OF PERFUSION CHROMATOGRAPHY WILL LEAD TECHNOLOGY EFFORTS
PERSEPTIVE BIOSYSTEMS AGREES TO ACQUIRE PERSEPTIVE TECHNOLOGIES II CORPORATION
PERSEPTIVE BIOSYSTEMS COMPLETES EXCHANGE OFFER FOR UNITS OF PERSEPTIVE TECHNOLOGIES II CORPORATION
PERSEPTIVE BIOSYSTEMS TO COMBINE ITS DRUG DISCOVERY GROUP WITH MYCO PHARMACEUTICALS TO FORM CHEMGENICS PHARMACEUTICALS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters